Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
Status: | Completed |
---|---|
Conditions: | Colorectal Cancer, Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 7/22/2018 |
Start Date: | February 16, 2015 |
End Date: | July 10, 2018 |
A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
This pilot clinical trial studies the feasibility of a low glycemic load diet in patients
with stage I-III colon cancer. A low glycemic load diet includes foods that have low scores
on the glycemic index. The glycemic index is a scale that measures how much a certain
carbohydrate causes a person's blood sugar to rise. A low glycemic load diet may help
decrease the chance of cancer coming back and improve the survival in patients with colon
cancer.
with stage I-III colon cancer. A low glycemic load diet includes foods that have low scores
on the glycemic index. The glycemic index is a scale that measures how much a certain
carbohydrate causes a person's blood sugar to rise. A low glycemic load diet may help
decrease the chance of cancer coming back and improve the survival in patients with colon
cancer.
PRIMARY OBJECTIVES:
I. To determine the feasibility of following a low or medium glycemic load diet in patients
with stage I-III (local-regional) colon cancer.
SECONDARY OBJECTIVES:
I. To determine patient-reported acceptability of diet. II. To determine nutritionist
resources utilized. III. To evaluate the effect of lowering dietary glycemic load on body
mass index (BMI), lipid metabolism and pro-oncogenic intermediaries of cellular metabolism.
OUTLINE: Patients are sequentially enrolled in 1 of 4 possible cohorts as needed based on the
feasibility of the prior cohort.
COHORT 1: Patients follow a low glycemic load diet with standard dietary intervention
(contact with nutritionist in person every 2 weeks with phone contact on the alternating
weeks) for 12 weeks.
COHORT 2: Patients follow a low glycemic load diet with intensified dietary intervention
(contact with nutritionist in person every week) for 12 weeks.
COHORT 3: Patients follow a medium glycemic load diet with standard dietary intervention for
12 weeks.
COHORT 4: Patients follow a medium glycemic load diet with intensified dietary intervention
for 12 weeks.
I. To determine the feasibility of following a low or medium glycemic load diet in patients
with stage I-III (local-regional) colon cancer.
SECONDARY OBJECTIVES:
I. To determine patient-reported acceptability of diet. II. To determine nutritionist
resources utilized. III. To evaluate the effect of lowering dietary glycemic load on body
mass index (BMI), lipid metabolism and pro-oncogenic intermediaries of cellular metabolism.
OUTLINE: Patients are sequentially enrolled in 1 of 4 possible cohorts as needed based on the
feasibility of the prior cohort.
COHORT 1: Patients follow a low glycemic load diet with standard dietary intervention
(contact with nutritionist in person every 2 weeks with phone contact on the alternating
weeks) for 12 weeks.
COHORT 2: Patients follow a low glycemic load diet with intensified dietary intervention
(contact with nutritionist in person every week) for 12 weeks.
COHORT 3: Patients follow a medium glycemic load diet with standard dietary intervention for
12 weeks.
COHORT 4: Patients follow a medium glycemic load diet with intensified dietary intervention
for 12 weeks.
Inclusion Criteria:
- Patients must have stage I-III colon or rectal cancer and have undergone definitive
therapy; definitive therapy may have included surgery alone, or surgery plus
neoadjuvant and/or adjuvant therapy
- Patients must regularly consume a diet with a glycemic load > 150 as estimated through
the 3 day food recall
- Patients must readily be available for a 3 month period and agree to participate in
regular dietary adherence assessments (surveys and phone interviews)
Exclusion Criteria:
- Current participation in an intervention targeting diet or exercise
We found this trial at
2
sites
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.844.8797
Principal Investigator: Neal Meropol
Phone: 216-844-5220
Case Comprehensive Cancer Center The Case Comprehensive Cancer Center (Case CCC) based at Case Western...
Click here to add this to my saved trials